Intranasal vaccination of New Zealand white rabbits against pasteurellosis, using alginate-encapsulated Pasteurella multocida toxin and potassium thiocyanate extract

Lamis Z. Jarvinen, Harm HogenEsch, Mark A. Suckow, Terry L. Bowersock

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: We evaluated the efficacy of intranasal administration of Pasteurella multocida toxin (PMT) and a potassium thiocyanate extract of P. multocida (CN) encapsulated in alginate microspheres, compared with unencapsulated PMT and CN antigens, in protection of rabbits against pasteurellosis. Methods: New Zealand male rabbits (n=24) were allotted randomly into four intranasally administered vaccine groups: 1, PMT/CN; 2, microencapsulated PMT/CN with or; 3, without subcutaneous priming; and 4, empty microspheres (control). Blood samples and nasal wash specimens were collected before vaccination and one week after each vaccination (days 7, 21, 35, and 49). Rabbits were primed subcutaneously with either unencapsulated PMT/CN or aluminum hydroxide (control) (day 0), vaccinated intranasally (days 14, 28, and 42), challenged intranasally with live P. multocida (day 56), and necropsied (day 60). Results: Compared with controls, PMT/CN-immunized rabbits had significantly higher concentrations of serum IgG and IgM, nasal IgG, and bronchoalveolar lavage fluid IgA and IgG against CN. Immunized rabbits had 100% survival rate and low numbers of bacteria in liver and lungs; the control group had 50% survival rate and higher numbers of bacteria (> 4x) per gram of tissue in liver and lungs. Conclusion: The PMT/CN microspheres stimulated systemic and mucosal immune responses similar in effectiveness (protection) to those in response to unencapsulated PMT/CN administration.

Original languageEnglish (US)
Pages (from-to)263-269
Number of pages7
JournalComparative Medicine
Volume50
Issue number3
StatePublished - Jun 2000
Externally publishedYes

Fingerprint

Pasteurella Infections
pasteurellosis
thiocyanates
New Zealand White rabbit
Pasteurella multocida
alginates
Vaccination
toxins
vaccination
potassium
Rabbits
extracts
Microspheres
rabbits
Immunoglobulin G
Liver
Bacteria
Nasal Lavage Fluid
Aluminum Hydroxide
Intranasal Administration

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Intranasal vaccination of New Zealand white rabbits against pasteurellosis, using alginate-encapsulated Pasteurella multocida toxin and potassium thiocyanate extract. / Jarvinen, Lamis Z.; HogenEsch, Harm; Suckow, Mark A.; Bowersock, Terry L.

In: Comparative Medicine, Vol. 50, No. 3, 06.2000, p. 263-269.

Research output: Contribution to journalArticle

@article{313a7aadf5cc4d85b1b2648fd62c18be,
title = "Intranasal vaccination of New Zealand white rabbits against pasteurellosis, using alginate-encapsulated Pasteurella multocida toxin and potassium thiocyanate extract",
abstract = "Objective: We evaluated the efficacy of intranasal administration of Pasteurella multocida toxin (PMT) and a potassium thiocyanate extract of P. multocida (CN) encapsulated in alginate microspheres, compared with unencapsulated PMT and CN antigens, in protection of rabbits against pasteurellosis. Methods: New Zealand male rabbits (n=24) were allotted randomly into four intranasally administered vaccine groups: 1, PMT/CN; 2, microencapsulated PMT/CN with or; 3, without subcutaneous priming; and 4, empty microspheres (control). Blood samples and nasal wash specimens were collected before vaccination and one week after each vaccination (days 7, 21, 35, and 49). Rabbits were primed subcutaneously with either unencapsulated PMT/CN or aluminum hydroxide (control) (day 0), vaccinated intranasally (days 14, 28, and 42), challenged intranasally with live P. multocida (day 56), and necropsied (day 60). Results: Compared with controls, PMT/CN-immunized rabbits had significantly higher concentrations of serum IgG and IgM, nasal IgG, and bronchoalveolar lavage fluid IgA and IgG against CN. Immunized rabbits had 100{\%} survival rate and low numbers of bacteria in liver and lungs; the control group had 50{\%} survival rate and higher numbers of bacteria (> 4x) per gram of tissue in liver and lungs. Conclusion: The PMT/CN microspheres stimulated systemic and mucosal immune responses similar in effectiveness (protection) to those in response to unencapsulated PMT/CN administration.",
author = "Jarvinen, {Lamis Z.} and Harm HogenEsch and Suckow, {Mark A.} and Bowersock, {Terry L.}",
year = "2000",
month = "6",
language = "English (US)",
volume = "50",
pages = "263--269",
journal = "Comparative Medicine",
issn = "1532-0820",
publisher = "American Association for Laboratory Animal Science",
number = "3",

}

TY - JOUR

T1 - Intranasal vaccination of New Zealand white rabbits against pasteurellosis, using alginate-encapsulated Pasteurella multocida toxin and potassium thiocyanate extract

AU - Jarvinen, Lamis Z.

AU - HogenEsch, Harm

AU - Suckow, Mark A.

AU - Bowersock, Terry L.

PY - 2000/6

Y1 - 2000/6

N2 - Objective: We evaluated the efficacy of intranasal administration of Pasteurella multocida toxin (PMT) and a potassium thiocyanate extract of P. multocida (CN) encapsulated in alginate microspheres, compared with unencapsulated PMT and CN antigens, in protection of rabbits against pasteurellosis. Methods: New Zealand male rabbits (n=24) were allotted randomly into four intranasally administered vaccine groups: 1, PMT/CN; 2, microencapsulated PMT/CN with or; 3, without subcutaneous priming; and 4, empty microspheres (control). Blood samples and nasal wash specimens were collected before vaccination and one week after each vaccination (days 7, 21, 35, and 49). Rabbits were primed subcutaneously with either unencapsulated PMT/CN or aluminum hydroxide (control) (day 0), vaccinated intranasally (days 14, 28, and 42), challenged intranasally with live P. multocida (day 56), and necropsied (day 60). Results: Compared with controls, PMT/CN-immunized rabbits had significantly higher concentrations of serum IgG and IgM, nasal IgG, and bronchoalveolar lavage fluid IgA and IgG against CN. Immunized rabbits had 100% survival rate and low numbers of bacteria in liver and lungs; the control group had 50% survival rate and higher numbers of bacteria (> 4x) per gram of tissue in liver and lungs. Conclusion: The PMT/CN microspheres stimulated systemic and mucosal immune responses similar in effectiveness (protection) to those in response to unencapsulated PMT/CN administration.

AB - Objective: We evaluated the efficacy of intranasal administration of Pasteurella multocida toxin (PMT) and a potassium thiocyanate extract of P. multocida (CN) encapsulated in alginate microspheres, compared with unencapsulated PMT and CN antigens, in protection of rabbits against pasteurellosis. Methods: New Zealand male rabbits (n=24) were allotted randomly into four intranasally administered vaccine groups: 1, PMT/CN; 2, microencapsulated PMT/CN with or; 3, without subcutaneous priming; and 4, empty microspheres (control). Blood samples and nasal wash specimens were collected before vaccination and one week after each vaccination (days 7, 21, 35, and 49). Rabbits were primed subcutaneously with either unencapsulated PMT/CN or aluminum hydroxide (control) (day 0), vaccinated intranasally (days 14, 28, and 42), challenged intranasally with live P. multocida (day 56), and necropsied (day 60). Results: Compared with controls, PMT/CN-immunized rabbits had significantly higher concentrations of serum IgG and IgM, nasal IgG, and bronchoalveolar lavage fluid IgA and IgG against CN. Immunized rabbits had 100% survival rate and low numbers of bacteria in liver and lungs; the control group had 50% survival rate and higher numbers of bacteria (> 4x) per gram of tissue in liver and lungs. Conclusion: The PMT/CN microspheres stimulated systemic and mucosal immune responses similar in effectiveness (protection) to those in response to unencapsulated PMT/CN administration.

UR - http://www.scopus.com/inward/record.url?scp=0033918887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033918887&partnerID=8YFLogxK

M3 - Article

C2 - 10894489

AN - SCOPUS:0033918887

VL - 50

SP - 263

EP - 269

JO - Comparative Medicine

JF - Comparative Medicine

SN - 1532-0820

IS - 3

ER -